Gensight Biologics : A minor impact on clinical and regulatory activity
>A minor impact on its clinical programme - Yesterday, Gensight's management discussed the impact of the current pandemic on its clinical and operating portfolio. The impact remains extremely moderate, unlike other companies in the industry. Indeed, the two major phase III trials REVERSE and RESCUE which will form the basis for the registration of Lumevoq (GS010) for the treatment of Leber hereditary optic neuropathy (LHON) have been completed. However, the long...GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.